S. Rafla
- Hematology top 10%
- Multiple Myeloma Research and Treatments 2
-
- Cerebrovascular and Carotid Artery Diseases 4
-
- Salivary Gland Tumors Diagnosis and Treatment 4
- Head and Neck Surgical Oncology 2
-
- Acute Ischemic Stroke Management 3
- Neuroendocrine Tumor Research Advances 2
-
- Advances in Oncology and Radiotherapy 3
-
- Protein Degradation and Inhibitors 2
- Co-authors
- E HendersonJanet CuttnerHoward R. TerebeloRT SilverRW CareyRR EllisonRobert M. JohnsonMorton Coleman
- Partner nations
- United StatesCanada
In The Last Decade
S. Rafla
26 papers receiving 430 citations
Peers
Comparison fields: 5 of 62
- Hematology 96
- Oncology 180
- Pulmonary and Respiratory Medicine 152
- Otorhinolaryngology 18
- Surgery 150
Countries citing papers authored by S. Rafla
This map shows the geographic impact of S. Rafla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Rafla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Rafla more than expected).
Fields of papers citing papers by S. Rafla
This network shows the impact of papers produced by S. Rafla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Rafla. The network helps show where S. Rafla may publish in the future.
Co-authorship network
The 25 scholars most cited alongside S. Rafla, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 0 | |
| 2 | 2023 | 2 | |
| 3 | 2021 | 3 | |
| 4 | 2019 | 7 | |
| 5 | 2019 | 2 | |
| 6 | 2019 | 10 | |
| 7 | 2018 | 1 | |
| 8 | 1997 | 7 | |
| 9 | 1991 | 9 | |
| 10 | 1989 | 5 | |
| 11 | 1988 | 5 | |
| 12 | Phase II trial of spirogermanium in advanced renal cell carcinoma: a Cancer and Leukemia Group B study. | 1984 | 6 |
| 13 | Phase II study of amsacrine in metastatic renal cell carcinoma: a Cancer and Leukemia Group B study. | 1983 | 1 |
| 14 | 1980 | 1 | |
| 15 | 1978 | 20 | |
| 16 | 1976 | 12 | |
| 17 | The treatment of advanced prostatic carcinoma with medroxyprogesterone. | 1974 | 11 |
| 18 | 1970 | 17 | |
| 19 | 1970 | 155 | |
| 20 | 1969 | 24 |
About S. Rafla
S. Rafla is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Hematology, Pulmonary and Respiratory Medicine and Radiation, having authored 27 papers that have together received 470 indexed citations. Recurring topics across this work include Cerebrovascular and Carotid Artery Diseases (4 papers), Salivary Gland Tumors Diagnosis and Treatment (4 papers), Acute Ischemic Stroke Management (3 papers), Advances in Oncology and Radiotherapy (3 papers), Head and Neck Surgical Oncology (2 papers), Neuroendocrine Tumor Research Advances (2 papers), Multiple Myeloma Research and Treatments (2 papers) and Protein Degradation and Inhibitors (2 papers). The work is most often cited by research in Hematology (96 citations), Oncology (180 citations), Pulmonary and Respiratory Medicine (152 citations), Otorhinolaryngology (18 citations) and Surgery (150 citations). S. Rafla has collaborated with scholars based in United States and Canada. Frequent co-authors include E Henderson, Janet Cuttner, Howard R. Terebelo, RT Silver, RW Carey, RR Ellison, Robert M. Johnson, Morton Coleman, M. Robert Cooper and S Kochwa. Their work appears in journals such as Cancer, Journal of Clinical Oncology, Scientific Reports, International Journal of Radiation Oncology*Biology*Physics and Injury.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.